Skip to main content
PMC home page
Journal of Medical Genetics logoLink to Journal of Medical Genetics
. 2005 May;42(5):390–395. doi: 10.1136/jmg.2004.027284

Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?

E Cadet 1, D Capron 1, M Gallet 1, M Omanga-Leke 1, H Boutignon 1, C Julier 1, K Robson 1, J Rochette 1
PMCID: PMC1736060  PMID: 15863667

Abstract

Background: Genetic testing can determine those at risk for hereditary haemochromatosis (HH) caused by HFE mutations before the onset of symptoms. However, there is no optimum screening strategy, mainly owing to the variable penetrance in those who are homozygous for the HFE Cys282Tyr (C282Y) mutation. The objective of this study was to identify the majority of individuals at serious risk of developing HFE haemochromatosis before they developed life threatening complications.

Methods: We first estimated the therapeutic penetrance of the C282Y mutation in people living in la Somme, France, using genetic, demographic, biochemical, and follow up data. We examined the benefits of neonatal screening on the basis of increased risk to relatives of newborns carrying one or two copies of the C282Y mutation. Between 1999 and 2002, we screened 7038 newborns from two maternity hospitals in the north of France for the C282Y and His63Asp (H63D) mutations in the HFE gene, using bloodspots collected on Guthrie cards. Family studies and genetic counselling were undertaken, based on the results of the baby's genotype.

Findings: In la Somme, we found that 24% of the adults homozygous for the C282Y mutation required at least 5 g iron to be removed to restore normal iron parameters (that is, the therapeutic penetrance). In the reverse cascade screening study, we identified 19 C282Y homozygotes (1/370), 491 heterozygotes (1/14) and 166 compound heterozygotes (1/42) in 7038 newborns tested. The reverse cascade screening strategy resulted in 80 adults being screened for both mutations. We identified 10 previously unknown C282Y homozygotes of whom six (four men and two women) required venesection. Acceptance of neonatal screening was high; parents understood the risks of having HH and the benefits of early detection, but a number of parents were reluctant to take the test themselves. Neonatal screening for HH is straightforward. Reverse cascade screening increased the efficiency of detecting affected adults with undiagnosed haemochromatosis. This strategy allows almost complete coverage for HH and could be a model for efficient screening for other late onset genetic diseases.

Full Text

The Full Text of this article is available as a PDF (91.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams P. C., Kertesz A. E., McLaren C. E., Barr R., Bamford A., Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 2000 May;31(5):1160–1164. doi: 10.1053/he.2000.6984. [DOI] [PubMed] [Google Scholar]
  2. Adams P. C., Valberg L. S. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999 Jun;94(6):1593–1600. doi: 10.1111/j.1572-0241.1999.1120_f.x. [DOI] [PubMed] [Google Scholar]
  3. Ajioka Richard S., Kushner James P. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood. 2003 May 1;101(9):3351–3358. doi: 10.1182/blood-2002-11-3453. [DOI] [PubMed] [Google Scholar]
  4. Allen K. J., Warner B., Delatycki M. B. Clinical haemochromatosis in HFE mutation carriers. Lancet. 2002 Aug 3;360(9330):412–414. doi: 10.1016/s0140-6736(02)09583-1. [DOI] [PubMed] [Google Scholar]
  5. Bacon B. R., Olynyk J. K., Brunt E. M., Britton R. S., Wolff R. K. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999 Jun 15;130(12):953–962. doi: 10.7326/0003-4819-130-12-199906150-00002. [DOI] [PubMed] [Google Scholar]
  6. Beutler Ernest, Felitti Vincent J., Koziol James A., Ho Ngoc J., Gelbart Terri. Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002 Jan 19;359(9302):211–218. doi: 10.1016/S0140-6736(02)07447-0. [DOI] [PubMed] [Google Scholar]
  7. Bulaj Z. J., Ajioka R. S., Phillips J. D., LaSalle B. A., Jorde L. B., Griffen L. M., Edwards C. Q., Kushner J. P. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000 Nov 23;343(21):1529–1535. doi: 10.1056/NEJM200011233432104. [DOI] [PubMed] [Google Scholar]
  8. Burke W., Thomson E., Khoury M. J., McDonnell S. M., Press N., Adams P. C., Barton J. C., Beutler E., Brittenham G., Buchanan A. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 1998 Jul 8;280(2):172–178. doi: 10.1001/jama.280.2.172. [DOI] [PubMed] [Google Scholar]
  9. Cadet E., Capron D., Perez A. S., Crépin S. N., Arlot S., Ducroix J-P, Dautréaux M., Fardellone P., Leflon P., Merryweather-Clarke A. T. A targeted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Med. 2003 Feb;253(2):217–224. doi: 10.1046/j.1365-2796.2003.01094.x. [DOI] [PubMed] [Google Scholar]
  10. Cox Timothy, Rochette Jacques, Camaschella Clara, Walker Ann, Robson Kathryn. Clinical haemochromatosis in HFE mutation carriers. Lancet. 2002 Aug 3;360(9330):412–414. doi: 10.1016/S0140-6736(02)09582-X. [DOI] [PubMed] [Google Scholar]
  11. Crawford D. H., Jazwinska E. C., Cullen L. M., Powell L. W. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology. 1998 May;114(5):1003–1008. doi: 10.1016/s0016-5085(98)70320-8. [DOI] [PubMed] [Google Scholar]
  12. Cullen L. M., Summerville L., Glassick T. V., Crawford D. H., Powell L. W., Jazwinska E. C. Neonatal screening for the hemochromatosis defect. Blood. 1997 Nov 15;90(10):4236–4237. [PubMed] [Google Scholar]
  13. Deugnier Yves, Jouanolle Anne-Marie, Chaperon Jacques, Moirand Romain, Pithois Catherine, Meyer Jean-François, Pouchard Michel, Lafraise Bernard, Brigand Alain, Caserio-Schoenemann Céline. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol. 2002 Sep;118(4):1170–1178. doi: 10.1046/j.1365-2141.2002.03718.x. [DOI] [PubMed] [Google Scholar]
  14. Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., Dormishian F., Domingo R., Jr, Ellis M. C., Fullan A. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996 Aug;13(4):399–408. doi: 10.1038/ng0896-399. [DOI] [PubMed] [Google Scholar]
  15. Jouanolle A. M., Gandon G., Jézéquel P., Blayau M., Campion M. L., Yaouanq J., Mosser J., Fergelot P., Chauvel B., Bouric P. Haemochromatosis and HLA-H. Nat Genet. 1996 Nov;14(3):251–252. doi: 10.1038/ng1196-251. [DOI] [PubMed] [Google Scholar]
  16. Krawczak M., Cooper D. N., Schmidtke J. Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet. 2001 Jun 26;69(2):361–370. doi: 10.1086/321973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McCune C. Anne, Al-Jader Layla N., May Alison, Hayes Sara L., Jackson Helen A., Worwood Mark. Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet. 2002 Sep 26;111(6):538–543. doi: 10.1007/s00439-002-0824-1. [DOI] [PubMed] [Google Scholar]
  18. McDonnell S. M., Phatak P. D., Felitti V., Hover A., McLaren G. D. Screening for hemochromatosis in primary care settings. Ann Intern Med. 1998 Dec 1;129(11):962–970. doi: 10.7326/0003-4819-129-11_part_2-199812011-00007. [DOI] [PubMed] [Google Scholar]
  19. McLaren C. E., McLachlan G. J., Halliday J. W., Webb S. I., Leggett B. A., Jazwinska E. C., Crawford D. H., Gordeuk V. R., McLaren G. D., Powell L. W. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology. 1998 Mar;114(3):543–549. doi: 10.1016/s0016-5085(98)70538-4. [DOI] [PubMed] [Google Scholar]
  20. Merryweather-Clarke A. T., Pointon J. J., Shearman J. D., Robson K. J. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997 Apr;34(4):275–278. doi: 10.1136/jmg.34.4.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Merryweather-Clarke A. T., Pointon J. J., Shearman J. D., Robson K. J., Jouanolle A. M., Mosser A., David V., Le Gall J. Y., Halsall D. J., Elsey T. S. Polymorphism in intron 4 of HFE does not compromise haemochromatosis mutation results. The European Haemochromatosis Consortium. Nat Genet. 1999 Nov;23(3):271–271. doi: 10.1038/15452. [DOI] [PubMed] [Google Scholar]
  22. Merryweather-Clarke A. T., Simonsen H., Shearman J. D., Pointon J. J., Nørgaard-Pedersen B., Robson K. J. A retrospective anonymous pilot study in screening newborns for HFE mutations in Scandinavian populations. Hum Mutat. 1999;13(2):154–159. doi: 10.1002/(SICI)1098-1004(1999)13:2<154::AID-HUMU8>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  23. Niederau C., Fischer R., Pürschel A., Stremmel W., Häussinger D., Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996 Apr;110(4):1107–1119. doi: 10.1053/gast.1996.v110.pm8613000. [DOI] [PubMed] [Google Scholar]
  24. Niederau C., Niederau C. M., Lange S., Littauer A., Abdel-Jalil N., Maurer M., Häussinger D., Strohmeyer G. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998 Mar 1;128(5):337–345. doi: 10.7326/0003-4819-128-5-199803010-00001. [DOI] [PubMed] [Google Scholar]
  25. Olynyk J. K., Cullen D. J., Aquilia S., Rossi E., Summerville L., Powell L. W. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999 Sep 2;341(10):718–724. doi: 10.1056/NEJM199909023411002. [DOI] [PubMed] [Google Scholar]
  26. Powell Lawrie W. Diagnosis of hemochromatosis. Semin Gastrointest Dis. 2002 Apr;13(2):80–88. [PubMed] [Google Scholar]
  27. Power T. E., Adams P. C. Psychosocial impact of C282Y mutation testing for hemochromatosis. Genet Test. 2001 Summer;5(2):107–110. doi: 10.1089/109065701753145556. [DOI] [PubMed] [Google Scholar]
  28. Rochette J., Capron D., Capron J. P., Julier C. Screening for hereditary hemochromatosis. Am J Gastroenterol. 2000 May;95(5):1368–1369. doi: 10.1111/j.1572-0241.2000.02044.x. [DOI] [PubMed] [Google Scholar]
  29. Wallace D. F., Dooley J. S., Walker A. P. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C282Y heterozygote. Gastroenterology. 1999 Jun;116(6):1409–1412. doi: 10.1016/s0016-5085(99)70505-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group

RESOURCES